Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab + MTX in Active RA with Inadequate Response to MTX
NCT00779220Phase 2Terminated
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2008
- Primary completion
- Feb 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ocrelizumab in rheumatoid arthritis (RA) (4 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: American College of Rheumatology 20% Response at 24 weeks. Started Oct 2008; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00779220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00779220.